Research Guide · AA-CJI-2026-29G
CJC-1295 + Ipamorelin
CJC-1295 No DAC 5mg + Ipamorelin 5mg Secretagogue Blend
CAS
N/A — Multi-Compound Blend
Mol. Weight
Multi-component
Purity
99.90%
Format
10mg Blend Vial
Overview
The CJC-1295 (No DAC) + Ipamorelin blend is the classic secretagogue research pairing: a GHRH analog combined with a selective ghrelin-receptor agonist pentapeptide in one lyophilized vial.
Mechanism of Action
Dual-receptor synergy documented in the literature: CJC-1295 stimulates the GHRH receptor while Ipamorelin acts on the ghrelin/GHS receptor — two distinct signals converging on pulsatile growth hormone release in preclinical models, without the cortisol or prolactin spillover seen with older secretagogues.
Dosing-Study Summary
Component literature — CJC-1295
30–60 µg/kg, subcutaneous
Sustained dose-dependent GH and IGF-1 elevation with preserved pulsatility (PubMed #16352683)
Component literature — Ipamorelin
µg/kg range (rodent/human PK)
Selective GH release without significant ACTH or cortisol elevation — the selectivity that made it a research standard
Combination rationale
Per component literature
GHRH + GHS receptor co-stimulation produces synergistic pulse amplitude greater than either alone in published models
Doses shown are reported in cited preclinical / clinical literature for research reference only — not usage recommendations.
Storage & Handling
Store lyophilized at -20°C protected from light. Reconstitute with bacteriostatic water under sterile technique; refrigerate at 2–8°C. Secretagogue peptides are oxidation-sensitive — minimize air exposure.
Citations
This guide summarizes published scientific literature for laboratory research reference. Alpha Amino compounds are for research use only — not for human or animal consumption. Nothing here constitutes medical or dosing advice.